The Gene Signature of Activated M-CSF-Primed Human Monocyte-Derived Macrophages Is IL-10-Dependent

Víctor D Cuevas1, Miriam Simón-Fuentes1, Emmanuel Orta-Zavalza1

  • 1Centro de Investigaciones Biológicas, CSIC, Madrid, Spain.

Insights

Monocyte-derived macrophages (M-MØ) activated by macrophage colony-stimulating factor (M-CSF) develop a unique gene signature. This signature, partly driven by IL-10, may offer targets for new macrophage-centered therapies.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • Monocytes infiltrate inflamed tissues, differentiating into pro-inflammatory monocyte-derived macrophages (MDMs) that drive pathology.
  • Pathogenic MDM subsets share transcriptional similarities with M-CSF-primed human macrophages (M-MØ).
  • M-MØ exhibit a distinct cytokine profile (IL10high, TFNlow, IL23low, IL6low) upon activation.

Purpose of the Study:

  • To elucidate the transcriptional signature of M-MØ upon stimulation with pathogenic factors.
  • To identify key signaling pathways and molecular players involved in M-MØ activation.
  • To explore the potential of M-MØ-associated gene sets for therapeutic strategies.

Main Methods:

  • Transcriptome analysis of activated M-MØ.
  • Investigation of signaling pathways including ERK/p38 and STAT3.
  • Gene set enrichment analysis and correlation with pathogenic macrophage markers (CD163, SPI1).
  • IL-10 neutralization experiments.

Main Results:

  • M-MØ activation induced a specific transcriptional profile (Gene set 1) linked to pathogenic macrophages in COVID-19 and TAMs.
  • Gene set 1 expression was dependent on ERK/p38 and STAT3 activation.
  • IL-10 was essential for a subset of Gene set 1 genes and contributed to the overall M-MØ signature.

Conclusions:

  • M-CSF-primed human macrophages acquire a distinctive gene expression profile upon activation.
  • This profile is partially regulated by IL-10 and involves ERK/p38 and STAT3 signaling.
  • The identified gene set holds potential for developing novel macrophage-targeted therapies.